Overview

A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients

Status:
Recruiting

Trial end date:
2022-09-01

Target enrollment:

Participant gender:

Summary

This is a multicentre, comparator-group, open-label, controlled, nonrandomised clinical study to compare the SPECT findings after a single IV administration of DaTSCAN™ ioflupane (123I) injection for patients with a clinical diagnosis of PS (SDD; specifically, patients with PD [SDD], MSA [SDD] or PSP [SDD]) as compared with patients with a clinical diagnosis of ET (no SDD) and age-matched healthy controls.

Phase:

Phase 3

Details

Lead Sponsor:

GE Healthcare

Collaborator:

PPD